Advancing First-in-Class Therapeutics
from
Our Biology-First AI Platform
Auransa's AI-Discovered Cancer Drug AU409 Shows Promising Clinical Activity — Hear from the Lead Clinical Investigator
WATCH NOW >>
Auransa's AI-Discovered Cancer Drug AU409 Shows Promising Clinical Activity — Hear from the Lead Clinical Investigator WATCH NOW >>
MEET AURANSA
We are a clinical stage, AI-native biopharma with a proprietary AI platform that harnesses available human disease data to discover novel therapeutics and raise the standard of cancer care.
From AI Discovery to Clinical Development
Our biology-first AI platform has delivered AU409, a novel, first-in-class cancer drug now in clinical trials, demonstrating the potential to translate human disease biology into meaningful therapeutic advances.
AU409
Auransa's AI-discovered, first-in-class oral cancer drug AU409 is being evaluated in a Phase 1 clinical trial, demonstrating encouraging antitumor activity, including a durable complete response* in a patient with advanced hepatocellular carcinoma.
*Complete response by modified RECIST (mRECIST), as reported by the clinical investigator; partial response by RECIST 1.1.
“As an early pioneer in genomics technology, first at Rosetta and later at Merck, I’ve long been a champion of the integration of data science into biological discovery. I am most excited by the next chapter; Auransa and the intersection of AI, biology, massive data, and precision medicine.”
Pek Lum, Co-Founder and CEO, Auransa